Takeda Completed A 7-year Pivotal Phase 3 TIDES Trial Evaluating Its Dengue Vaccine, Qdenga (TAK-003), Showing A Favorable Benefit And Risk Profile Of Qdenga And That Two-dose Regimen Provides Sustained Protection Against Dengue

Author: Benzinga Newsdesk | November 03, 2025 07:05am

After 4.5 years, two doses of QDENGA provided 61.2% [95% CI: 56.0, 65.8] vaccine efficacy (VE) in preventing virologically confirmed dengue (VCD).1 A booster dose administered at 4.5 years only marginally increased efficacy to 74.3% [95% CI: 66.7, 80.1] after 2 years.2 QDENGA showed 84.1% [95% CI: 77.8, 88.6] VE in preventing dengue-related hospitalizations at 4.5 years, and VE remained consistently high at 90.6% [95% CI: 78.9, 95.8] after the booster dose.1,2 Overall efficacy was seen across all four dengue virus serotypes through seven years. No new safety signals were observed following the administration of a booster dose.

Posted In: TAK